The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease

Documenti analoghi

• Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease
  di: Victor Wasehuus, et al.
  Pubblicazione: (2025)
• Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
  di: Stefan R. Bornstein, et al.
  Pubblicazione: (2024)
• Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
  di: Peter Rossing, et al.
  Pubblicazione: (2024)
• Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS
  di: Fatema Said, et al.
  Pubblicazione: (2024)
• Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study
  di: Anjaly Vijayan, et al.
  Pubblicazione: (2025)